» Articles » PMID: 36639608

Long COVID: Major Findings, Mechanisms and Recommendations

Overview
Date 2023 Jan 13
PMID 36639608
Authors
Affiliations
Soon will be listed here.
Abstract

Long COVID is an often debilitating illness that occurs in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. More than 200 symptoms have been identified with impacts on multiple organ systems. At least 65 million individuals worldwide are estimated to have long COVID, with cases increasing daily. Biomedical research has made substantial progress in identifying various pathophysiological changes and risk factors and in characterizing the illness; further, similarities with other viral-onset illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome and postural orthostatic tachycardia syndrome have laid the groundwork for research in the field. In this Review, we explore the current literature and highlight key findings, the overlap with other conditions, the variable onset of symptoms, long COVID in children and the impact of vaccinations. Although these key findings are critical to understanding long COVID, current diagnostic and treatment options are insufficient, and clinical trials must be prioritized that address leading hypotheses. Additionally, to strengthen long COVID research, future studies must account for biases and SARS-CoV-2 testing issues, build on viral-onset research, be inclusive of marginalized populations and meaningfully engage patients throughout the research process.

Citing Articles

Risk, determinants, and persistence of long-COVID in a population-based cohort study in Catalonia.

Kogevinas M, Karachaliou M, Espinosa A, Iraola-Guzman S, Castano-Vinyals G, Delgado-Ortiz L BMC Med. 2025; 23(1):140.

PMID: 40082863 PMC: 11907888. DOI: 10.1186/s12916-025-03974-7.


Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever.

Sun D, Lien T, Chang H Int J Mol Sci. 2025; 26(5).

PMID: 40076527 PMC: 11899886. DOI: 10.3390/ijms26051898.


Health-related quality of life in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post COVID-19 Condition: a systematic review.

Weigel B, Inderyas M, Eaton-Fitch N, Thapaliya K, Marshall-Gradisnik S J Transl Med. 2025; 23(1):318.

PMID: 40075382 PMC: 11905571. DOI: 10.1186/s12967-025-06131-z.


Anti-interferon armamentarium of human coronaviruses.

Khatun O, Kaur S, Tripathi S Cell Mol Life Sci. 2025; 82(1):116.

PMID: 40074984 PMC: 11904029. DOI: 10.1007/s00018-025-05605-z.


TGFβ links EBV to multisystem inflammatory syndrome in children.

Goetzke C, Massoud M, Frischbutter S, Guerra G, Ferreira-Gomes M, Heinrich F Nature. 2025; .

PMID: 40074901 DOI: 10.1038/s41586-025-08697-6.


References
1.
Davis H, Assaf G, McCorkell L, Wei H, Low R, Reem Y . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38:101019. PMC: 8280690. DOI: 10.1016/j.eclinm.2021.101019. View

2.
Esfandyarpour R, Kashi A, Nemat-Gorgani M, Wilhelmy J, Davis R . A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Proc Natl Acad Sci U S A. 2019; 116(21):10250-10257. PMC: 6535016. DOI: 10.1073/pnas.1901274116. View

3.
Crooks V, Waller S, Smith T, Hahn T . The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991; 46(4):M139-44. DOI: 10.1093/geronj/46.4.m139. View

4.
Edlow A, Castro V, Shook L, Kaimal A, Perlis R . Neurodevelopmental Outcomes at 1 Year in Infants of Mothers Who Tested Positive for SARS-CoV-2 During Pregnancy. JAMA Netw Open. 2022; 5(6):e2215787. PMC: 9185175. DOI: 10.1001/jamanetworkopen.2022.15787. View

5.
Almufarrij I, Munro K . One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms. Int J Audiol. 2021; 60(12):935-945. DOI: 10.1080/14992027.2021.1896793. View